The Effect of Ozone Therapy for Lumbar Herniated Disc
Launched by KOVACS FOUNDATION · Nov 29, 2007
Trial Information
Current as of June 19, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of herniated disc by surgeons from participating hospitals
- • Sciatic pain of 5 or more on Visual Analogue Scale
- • Pain radiated to appropriate area according to herniated disc
- • On waiting list for disc surgery at one of participating hospitals
- Exclusion Criteria:
- • Inability to fill out questionnaires (VAS, Roland Morris, SF12)
- • Calcified or migrated herniated disc
- • Herniated disc with indications for laminectomy or arthrodesis
- • Clinically relevant partial paralysis
- • Simultaneous cervical and dorsal symptomatic herniated discs
- • Previous lumbar spine surgery
- • Presence of other spinal pathology
- • Significant glucose-6-phosphate-dehydrogenase deficit
- • Allergy to ozone
- • Treatment with oral anticoagulants
About Kovacs Foundation
The Kovacs Foundation is a leading nonprofit organization dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to scientific excellence and ethical standards, the foundation collaborates with healthcare professionals, academic institutions, and industry partners to facilitate groundbreaking studies in various therapeutic areas. By prioritizing patient safety and fostering an environment of transparency, the Kovacs Foundation strives to accelerate the development of effective treatments and enhance the quality of life for individuals affected by chronic and debilitating conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Las Palmas De Gran Canaria, Canary Islands, Spain
Patients applied
Trial Officials
Francisco M Kovacs, MD, PhD
Study Chair
Kovacs Foundation, Palma de Mallorca, 07012, Spain
Bernardino Clavo, MD
Study Director
Hospital Negrín, Las Palmas de Gran Canaria, 35010 Spain
Francisco Robaina, MD
Principal Investigator
Hospital Negrín, Las Palmas de Gran Canaria 35010 Spain
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials